Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





New, Portable COVID-19 Saliva-Based Testing Device to Deliver Results in as Little as 20 Minutes

By LabMedica International staff writers
Posted on 28 Sep 2020
Researchers at Arizona State University (ASU Tempe, AZ, USA) are developing a new, portable saliva-based testing device that will deliver results in as little as 20 minutes.

In May, researchers at ASU’s Biodesign Institute produced the Western United States’ first FDA-approved saliva-based COVID-19 test - one of only a handful available in the country - with test results delivered in 24–48 hours. More...
The team is now building a new, portable saliva-based testing device, also referred to as a point-of-need test, which will allow users to easily provide a saliva sample on a computer chip that will quickly detect whether the virus is present. The project is being funded by USD 5.2 million in CARES Act dollars from the governor’s office and USD 860,000 from the Arizona Department of Health Services.

The new rapid saliva test detects the viral RNA and combines the ease of use and speed of the newly FDA-approved antigen tests with greater accuracy similar to PCR-based RNA tests. If the virus is detected, a strong, green fluorescent signal is generated on the device. Also, unlike the PCR method, which needs a few hours of time because of several steps performed at different temperature cycles, this device is being designed to have all of the reactions performed at the same temperature.

A key point of the project will be mobility. Researchers envision a "plug and play" cartridge system that could be used by the ASU Biodesign Institute saliva-testing robotics system or implemented by practitioners without needing extensive training. By keeping the device small and portable, it can be rapidly employed and scaled in case of a surge in infection and done so locally and in a distributed fashion.

The ultimate goal is to have these devices accessible in public places such as doctors’ offices, workplaces and other densely populated areas. Through early detection, preventative measures can minimize contact risk and ensure safe spaces. Although the project is expected to generate working prototypes in six months and apply for FDA emergency-use authorization approval for COVID-19 testing, the team has already worked to align their technology with several companies for scalable production.

“We are of the view that this virus will be with us in some capacity for the foreseeable future; therefore, we need to develop the most sophisticated tools in order to help manage it,” said ASU President Michael M. Crow.

“Ultimately, we want to produce something easy to use so anyone could ‘spit on a chip’ while waiting for results for a few minutes and then be cleared for everyday activities or events, or rapidly isolated or ID’d as infected,” said Mark Hayes, one of the ASU professors leading the efforts to develop the new COVID-19 testing device.

Related Links:
Arizona State University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
SARS-CoV-2 RT PCR Kit
SARS-CoV-2 Variant Lambda (C.37) Real Time PCR Kit (RUO)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.